Curanex Pharmaceuticals (CURX) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($8.3 million vs $7.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CURX | LGVN |
|---|---|---|
| Share price | $5.31 | $2.48 |
| Market cap | $8.33M | $7.91M |
| 1-day change | +11.55% | +4.64% |
| EPS (TTM) | $-7.80 | $-9.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.94 | $12.30 |
| 52-week low | $3.58 | $2.30 |
| Distance from 52-week high | -68.65% | -79.84% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2369.76% |
| Average volume | 20.04K | 93.11K |
| Shares outstanding | 1.57M | 3.04M |
| Employees | 6 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
CURX vs LGVN FAQ
Which is bigger, Curanex Pharmaceuticals or Longeveron?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $8.33M compared with $7.91M for Longeveron (LGVN).
Are Curanex Pharmaceuticals and Longeveron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.